Home » Clinical Trials » Therapeutic Areas

Therapeutic Areas: Gastroenterology | Family Medicine
Disease Category: Crohn's Disease
Location: United States, FL

Clinical Trial Details

Overview

Research Study Summary

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Purpose

The primary objective of this study is to evaluate the efficacy of filgotinib as compared to placebo in establishing combined fistula response at Week 24. Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.

To Learn more

CW ID: 225899
Date Last Changed: August 11, 2017

Clinical Trial Snapshot

Phase
2
Gender
Both Male and Female
Age
18 to 75 Years
Overall Status
Recruiting
Lead Sponsor
Gilead Sciences
Facility Type
N/A

Eligibility

Key Inclusion Criteria:
  • Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on the date of screening visit
  • Diagnosis of Crohn's disease (CD) with a minimum duration of CD of at least 3 months
  • Has draining perianal fistulae as a complication of CD, confirmed by MRI at screening.
  • Previously demonstrated an inadequate clinical response, loss of response to, or intolerance of at least 1 of the following agents (depending on current country treatment recommendations/guidelines):
    • Antibiotics
    • Immunomodulators
    • TNFa Antagonist
    • Is willing and able to undergo MRI per protocol requirements
    • Is willing and able to undergo flexible sigmoidoscopy per protocol requirements
Key Exclusion Criteria:
  • Presence of current rectovaginal fistula
  • Presence of ulcerative colitis (UC), indeterminate colitis, ischemic colitis, fulminant colitis, or toxic mega-colon
  • History of total proctocolectomy, total colectomy, presence of ileostomy or colostomy, or likely requirement for surgery during the study
  • Use of any prohibited concomitant medications as described in the study protocol
  • Active tuberculosis (TB) or history of latent TB that has not been treated

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

More Info

GS-US-419-4016

Contact

Rachel Karlnoski
University of South Florida - South Tampa Center for Advanced Healthcare
2 Tampa General Circle
Tampa, FL 33606
Phone: (813) 844-4133

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.